Abstract
Background: To investigate the clinical characteristics, treatment and outcomes of myasthenia gravis with antibodies to the muscle-specific tyrosine kinase (MuSK-MG).Methods: We retrospectively reviewed 21 patients with confirmed MuSK-MG between January 2012 to January 2020 in our center. Detailed clinical data and long-term follow up information were summarized.Results: Females (17/21, 81%) predominated in MuSK-MG and the mean age of onset in this group was 51.86±16.16 years. MuSK-MG patients was divided into three subgroups according to the symptom of muscle weakness at onset: ocular myasthenia gravis (OMG, 47.6%), bulbar myasthenia gravis (BMG, 42.9%), and generalized myasthenia gravis (GMG, 9.5%). The mean progression time from symptoms onset to other muscle groups involvement in OMG patients was 4.38±2.54 months. Pyridostigmine bromide was adopted in 81.0% patients and 90.5% patients received corticosteroids. Compared to the usage in hospital, the median daily dose of corticosteroids decreased significantly at the last follow-up. 85.7% patients received a long-term follow-up with an average time of 1202.17 ± 976.73 days. At the end of the follow-up period: 4.8% patient received complete stable remission, 42.9% patients were in minimal manifestations, 19.0% had improved, 4.8% experienced an unchanged condition and 9.5% patients died.Conclusion: Female patients were more prevalent in this study and MuSK-MG patients had a rapid progress to a generalized state. Although about 50% MuSK-MG patients can achieve a favorable outcome with conventional immunosuppressants, complete stable remission is rare and about 15% respond poorly, more effective medications should be explored in these patients.